BiolevoxTMHA 2.2% is a hyaluronic acid (HA) gel designed for a three intra-articular injection
into the osteoarthritis (OA) affected in order to ameliorate symptoms of the
osteoarthritis (OA) in synovial joint.
Designed HA-based gel contains 44 mg of hyaluronate in 2 mL pre-filled syringe. The combination of high concentration of hyaluronate and optimally high molecular weight creates gel characterized with optimally high viscosity and elasticity1. With those properties Biolevox™ HA 2.2% is an ideal solution for a triple intra-articular injection viscosupplementation therapy.
As a result, BiolevoxTM HA 2.2% is able to effectively lubricate cartilaginous surfaces and absorb the shocks that occurs during movement of the joint, as well as extinguish OA symptoms like ongoing inflammation and thus significantly improve OA patient’s quality of life2. Treatment with three doses may provide more than twice the amount of acid than the other formulations of the same type.
Conclusively, treatment with three doses of Biolevox™ HA 2.2% is able to ameliorate OA symptoms like pain and joint mobility limitation and thus significantly improve OA patient’s quality of life3.
Designed HA-based gel contains 44 mg of hyaluronate in 2 mL pre-filled syringe. The combination of high concentration of hyaluronate and optimally high molecular weight creates gel characterized with optimally high viscosity and elasticity1. With those properties Biolevox™ HA 2.2% is an ideal solution for a triple intra-articular injection viscosupplementation therapy.
As a result, BiolevoxTM HA 2.2% is able to effectively lubricate cartilaginous surfaces and absorb the shocks that occurs during movement of the joint, as well as extinguish OA symptoms like ongoing inflammation and thus significantly improve OA patient’s quality of life2. Treatment with three doses may provide more than twice the amount of acid than the other formulations of the same type.
Conclusively, treatment with three doses of Biolevox™ HA 2.2% is able to ameliorate OA symptoms like pain and joint mobility limitation and thus significantly improve OA patient’s quality of life3.